> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panel to Discuss Zejula Supplemental NDA
- URL: https://www.fdaweb.com/panel-to-discuss-zejula-supplemental-nda/
- Published: 2022-09-21T12:00:00.000Z
- Updated: 2026-09-14T18:00:02.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5152787

*Federal Register* notice: FDA has announced an 11/22 Oncologic Drugs Advisory Committee meeting to discuss a GlaxoSmithKline supplemental NDA for Zejula (niraparib) capsules. Panel members will discuss the drug’s use for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Specifically, they will consider whether the indication should remain in the label based on final overall survival data from the NOVA trial. To view the notice, click [here](https://public-inspection.federalregister.gov/2022-20524.pdf?ref=fdaweb.com).